Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study - PubMed (original) (raw)

Randomized Controlled Trial

. 2015 Dec;110(3):e27-30.

doi: 10.1016/j.diabres.2015.09.009. Epub 2015 Sep 21.

Affiliations

Randomized Controlled Trial

Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Sun Hwa Kim et al. Diabetes Res Clin Pract. 2015 Dec.

Abstract

We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.

Keywords: Clinical trial; Lobeglitazone; Randomised trial; Thiazolidinediones.

Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources